Roche files sBLA for Lunsumio-Polivy combo in relapsed LBCL
Roche has announced that the FDA has accepted its supplemental Biologics License Application for a combination of Lunsumio VELO (mosunetuzumab, subcutaneous formulation) and Polivy (polatuzumab vedotin) in adult patients with relapsed or refractory large B-cell lymphoma who have received at least one prior line of systemic therapy. The agency is expected to deliver a decision by 9 February 2027.
The filing is supported by the phase III SUNMO trial, which enrolled patients ineligible for autologous stem cell transplant. At a median follow-up of 23.2 months, the combination reduced the risk of disease progression or death by 59% compared with rituximab, gemcitabine and oxaliplatin (R-GemOx), producing a hazard ratio of 0.41 (95% CI: 0.28–0.61; p<0.0001). Median progression-free survival was 11.5 months with the Lunsumio-Polivy regimen versus 3.8 months for R-GemOx. The cytokine release syndrome rate was roughly one in four patients, with fewer than 5% experiencing Grade 2 or 3 events, which Roche positions as a manageable safety profile relative to other T-cell engaging approaches in lymphoma.
Clinical context
Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, described relapsed or refractory LBCL as representing "one of the highest unmet needs in lymphoma care" and said the combination could offer "an important chemotherapy-free, outpatient-ready option" if approved.
The disease context is significant. LBCL, predominantly diffuse large B-cell lymphoma, accounts for more than 18,000 new diagnoses per year in the United States. Roughly 40% of patients relapse or develop refractory disease after frontline treatment, at which point the prognosis deteriorates sharply. Access to the most intensive salvage options, particularly CAR-T cell therapies, is constrained by geography, referral complexity and the logistics of care at specialist transplant centres. A subcutaneous, outpatient-capable regimen has practical appeal in a patient population that is often treated in community oncology settings rather than academic centres.
Updated SUNMO data presented at ASCO 2026 and the European Haematology Association Congress in June 2026 showed sustained clinical benefit in PFS, particularly among second-line patients, with no new safety signals at extended follow-up.
Competitive landscape
The r/r LBCL space has become one of the more contested segments in haematological oncology. CD19-directed CAR-T therapies from Kite and Bristol Myers Squibb hold approvals in the second-line setting, but their logistical demands remain a structural limitation for broad community uptake. Bispecific antibodies more broadly, including glofitamab (Roche's own Columvi) and epcoritamab from AbbVie and Genmab, are also active in LBCL. The Lunsumio-Polivy combination differentiates partly through its CD20xCD3 plus ADC mechanism and partly through its outpatient delivery profile, though head-to-head data against CAR-T or other bispecifics in the second-line setting do not yet exist in the public domain.
Mosunetuzumab already holds approval in third-line or later follicular lymphoma in both IV and subcutaneous formulations. If the sBLA is approved in LBCL, it would represent a meaningful expansion of the label into an earlier and more aggressive disease context, and would likely reinforce Roche's argument for mosunetuzumab as a platform asset across B-cell malignancies. Investors will watch the PDUFA date of 9 February 2027 alongside readouts from the phase III CELESTIMO study in follicular lymphoma, which could further broaden the commercial footprint.